Last reviewed · How we verify

Bepreve — Competitive Intelligence Brief

Bepreve (Bepreve) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Other.

marketed Histamine H1 receptor Other Small molecule Live · refreshed every 30 min

Target snapshot

Bepreve (Bepreve) — North Texas Institute for Clinical Trials.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Bepreve TARGET Bepreve North Texas Institute for Clinical Trials marketed Histamine H1 receptor
Lastacaft ALCAFTADINE AbbVie marketed Histamine-1 Receptor Antagonist [EPC] Histamine H1 receptor 2010-01-01
Xyzal LEVOCETIRIZINE Sanofi marketed Histamine-1 Receptor Antagonist Histamine H1 receptor 2007-01-01
Elestat EPINASTINE AbbVie marketed Adrenergic Receptor Agonist Histamine H1 receptor 2003-01-01
Rupax RUPATADINE Teikoku Seiyaku marketed rupatadine Histamine H1 receptor 2001-01-01
Zaditor KETOTIFEN marketed Histamine-1 Receptor Inhibitor Histamine H1 receptor 1999-01-01
Mizollen MIZOLASTINE Sanofi marketed mizolastine Histamine H1 receptor 1998-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bepreve — Competitive Intelligence Brief. https://druglandscape.com/ci/bepreve. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: